Kimberley S. Samkoe,1 Jonathan T. Elliott,2 Lei Wang,3 Summer Gibbs,3 Kenneth M. Tichauer4
1Dartmouth College (United States) 2Dartmouth-Hitchcock Medical Ctr. (United States) 3Oregon Health & Science Univ. (United States) 4Illinois Institute of Technology (United States)
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The failure rate of drug development is high, especially in Phase III clinical trials after significant time and monetary investment. This can be observed in oncology trials, where drug failure rates are much higher than non-oncological trials due to inadequate improvement in overall survival. To address this problem, we propose the use of fluorescence paired-agent imaging (PAI) to monitor drug-receptor interactions in vivo in individual patients. Therapeutic agents can be conjugated to fluorophores used for measuring target-specific interactions. Our preclinical progress will be discussed for both oncology and non-oncology applications with promising translation to clinical applications in the future.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Kimberley S. Samkoe, Jonathan T. Elliott, Lei Wang, Summer Gibbs, Kenneth M. Tichauer, "Paired-agent imaging for measuring drug-target interactions in vivo," Proc. SPIE PC12821, Visualizing and Quantifying Drug Distribution in Tissue VIII, PC1282102 (13 March 2024); https://doi.org/10.1117/12.3008552